<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35378738</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2666-6219</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Current problems in cancer. Case reports</Title>
          <ISOAbbreviation>Curr Probl Cancer Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review.</ArticleTitle>
        <Pagination>
          <StartPage>100153</StartPage>
          <MedlinePgn>100153</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cpccr.2022.100153</ELocationID>
        <Abstract>
          <AbstractText>Introduction COVID-19 disease has caused a global health and economic crisis. The introduction of the different COVID-19 vaccines has resulted in a significant decrease in the morbidity and mortality associated with this disease. Adverse effects have been reported, including cardiological ones such as myocarditis or pericarditis after administration. Likewise, tyrosine kinase inhibitor drugs such as osimertinib used in lung cancer patients with epidermal growth factor receptor (EGFR) mutation are associated with heart failure or prolongation of the QT interval. Case report 62-year-old woman diagnosed in September 2019 of lung adenocarcinoma stage IV with bilateral lung and lymph node involvement, carrier of an EGFR mutation (Ex19Del) on treatment with osimertinib. She attended emergency department for fever and hypotension 24 h after administration of the third dose of Moderna® COVID-19 vaccine in the context of acute myocarditis with evidence of severe left ventricular (LV) dysfunction in cardiogenic shock. She required vasoactive support, non-invasive mechanical ventilation, corticotherapy, immunoglobulins and subsequent ventricular support with Impella, with improvement of the clinical picture after 3 days. Cardiac magnetic resonance imaging (MRI) showed evidence of global myocardial oedema compatible with acute myocarditis. Coronary CT showed a lesion in the anterior descending coronary artery requiring revascularization. A few days later, she presented febrile symptoms with isolation of Staphylococcus aureus in the central line catheter and antibiotherapy with cloxacillin was started, with subsequent resolution of the infectious symptoms. Conclusion This is an exceptional and controversial case of fulminant myocarditis probably related to the Modern COVID-19 vaccine in a patient diagnosed with metastatic lung adenocarcinoma on treatment with osimertinib. An increasing number of cases of myocarditis and pericarditis have been reported following vaccination with COVID-19 mRNA vaccines. In addition, retrospective data have shown an increased risk of QT prolongation and heart failure in patients treated with tyrosine kinase inhibitors. Hence, the need for close monitoring of cardiac function during treatment of these patients. Future studies will be necessary to evaluate unknown adverse reactions of these vaccines and their possible interaction with other antineoplastic drugs.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Terán Brage</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roldán Ruíz</LastName>
            <ForeName>Jonnathan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>González Martín</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cardiology Department, University Hospital of Salamanca, 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oviedo Rodríguez</LastName>
            <ForeName>Juan Diego</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cardiology Department, University Hospital of Salamanca, 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vidal Tocino</LastName>
            <ForeName>Rosario</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodríguez Diego</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cardiology Department, University Hospital of Salamanca, 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sánchez Hernández</LastName>
            <ForeName>Pedro Luis</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cardiology Department, University Hospital of Salamanca, 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellido Hernández</LastName>
            <ForeName>Lorena</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fonseca Sánchez</LastName>
            <ForeName>Emilio</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente,58, Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute for Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Probl Cancer Case Rep</MedlineTA>
        <NlmUniqueID>9918231203906676</NlmUniqueID>
        <ISSNLinking>2666-6219</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19 mRNA vaccine</Keyword>
        <Keyword MajorTopicYN="N">Lung adenocarcinoma</Keyword>
        <Keyword MajorTopicYN="N">Myocarditis</Keyword>
        <Keyword MajorTopicYN="N">Osimertinib</Keyword>
      </KeywordList>
      <CoiStatement>None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35378738</ArticleId>
        <ArticleId IdType="pmc">PMC8968161</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cpccr.2022.100153</ArticleId>
        <ArticleId IdType="pii">S2666-6219(22)00017-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Boukhris M., Hillani A., Moroni F., Annabi M.S., Addad F., Ribeiro M.H., et al.  Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can. J. Cardiol. 2020;36(7):1068–1080. doi: 10.1016/j.cjca.2020.05.018. Jul.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cjca.2020.05.018</ArticleId>
            <ArticleId IdType="pmc">PMC7229739</ArticleId>
            <ArticleId IdType="pubmed">32425328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Møller R., et al.  Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045. doi: 10.1016/j.cell.2020.04.026. May 28e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId>
            <ArticleId IdType="pmc">PMC7227586</ArticleId>
            <ArticleId IdType="pubmed">32416070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. doi: 10.1016/S0140-6736(21)00947-8. May 15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId>
            <ArticleId IdType="pmc">PMC8099315</ArticleId>
            <ArticleId IdType="pubmed">33964222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez Bernal J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088. May 13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId>
            <ArticleId IdType="pmc">PMC8116636</ArticleId>
            <ArticleId IdType="pubmed">33985964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salah H.M., Mehta J.L. COVID-19 vaccine and myocarditis. Am. J. Cardiol. 2021;157:146–148. doi: 10.1016/j.amjcard.2021.07.009. Oct 15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2021.07.009</ArticleId>
            <ArticleId IdType="pmc">PMC8272967</ArticleId>
            <ArticleId IdType="pubmed">34399967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minocha P.K., Better D., Singh R.K., Hoque T. Recurrence of acute myocarditis temporally associated with receipt of the mRNA COVID-19 vaccine in an adolescent male. J. Pediatr. 2021;238:321–323. doi: 10.1016/j.jpeds.2021.06.035. Nov.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2021.06.035</ArticleId>
            <ArticleId IdType="pmc">PMC8216855</ArticleId>
            <ArticleId IdType="pubmed">34166671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H., et al.  Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137. Jan 11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1713137</ArticleId>
            <ArticleId IdType="pubmed">29151359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anand K., Ensor J., Trachtenberg B., Bernicker E.H. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS) J. Am. Coll. Cardiol. CardioOncol. 2019;1:172–178. doi: 10.1016/j.jaccao.2019.10.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaccao.2019.10.006</ArticleId>
            <ArticleId IdType="pmc">PMC8352117</ArticleId>
            <ArticleId IdType="pubmed">34396179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose N.R. Viral myocarditis. Curr. Opin. Rheumatol. 2016;28(4):383–389. doi: 10.1097/BOR.0000000000000303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0000000000000303</ArticleId>
            <ArticleId IdType="pmc">PMC4948180</ArticleId>
            <ArticleId IdType="pubmed">27166925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezkalla S.H., Kloner R.A. Viral myocarditis: 1917–2020: from the influenza A to the COVID-19 pandemics. Trends Cardiovasc. Med. 2021;31(3):163–169. doi: 10.1016/j.tcm.2020.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcm.2020.12.007</ArticleId>
            <ArticleId IdType="pmc">PMC7965406</ArticleId>
            <ArticleId IdType="pubmed">33383171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 2021;384(22):2092–2101. doi: 10.1056/NEJMoa2104840. Jun 3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId>
            <ArticleId IdType="pmc">PMC8095372</ArticleId>
            <ArticleId IdType="pubmed">33835769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel G., Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science. 2021 https://www.sciencemag.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination</Citation>
        </Reference>
        <Reference>
          <Citation>Mok T.S., Wu Y.L., Ahn M.J., Garassino M.C., Kim H.R., Ramalingam S.S., et al.  Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 2017;376(7):629–640. doi: 10.1056/NEJMoa1612674. Feb 16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1612674</ArticleId>
            <ArticleId IdType="pmc">PMC6762027</ArticleId>
            <ArticleId IdType="pubmed">27959700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi L., Fan J., Qian R., Luo P., Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: a meta-analysis. Int. J. Cancer. 2019;145(1):284–294. doi: 10.1002/ijc.32097. Jul 1doi: 10.1002/ijc.32097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32097</ArticleId>
            <ArticleId IdType="pmc">PMC6590181</ArticleId>
            <ArticleId IdType="pubmed">30613959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oyakawa T., Nakashima K., Naito T. Cardiac dysfunction caused by osimertinib. J. Thorac. Oncol. 2017;12(10):e159–e160. doi: 10.1016/j.jtho.2017.05.016. Oct.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2017.05.016</ArticleId>
            <ArticleId IdType="pubmed">28939147</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
